Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Official Title

Randomized Trial of ACEIs in Treatment of COVID-19

Brief Summary

ACEIs as treatment for COVID19

Detailed Description

ACEIs as suggested treatment for COVID19

Status

Not yet recruiting

Conditions

COVID

Interventions

Drug: ACEIs

Captopril or enalapril
Other Name: Enalapril, Captopril

Drug: Conventional treatment

alexoquine
Other Name: chloroquine

Eligibility Criteria

Inclusion Criteria:

- Patients infected with covid 19

Exclusion Criteria:

- allergy or contraindications to the drug

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

Egypt

Locations

Tanta University
Tanta, Egypt

Contacts

Sherief Abd-Elsalam
+201147773440
sheriefabdelsalam@yahoo.com

Investigators

Sherief Abd-Elsalam, ass. prof., Principal Investigator
Tanta University Faculty of medicine

NCT Number

NCT04345406

MeSH Terms

Chloroquine

Enalapril

Captopril

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA